← Leaderboards
Jonathan D Posner
University Of Washington
$6,109,307
Attributed
$8,023,541
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,023,541 · 4
By mechanism
R01$7,595,916 · 3
R21$427,625 · 1
Top collaborators
- Paul K Drain5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Ann E Kurth$9,873,452
- Alan J Herr$1,800,055
- Jeffrey Scott Duchin$3,497,078
- Mehul Shamal Suthar$8,747,894
- Carey Farquhar$27,772,472
Others in their field
Other Emerging Leaders on “Laboratories”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$463,311,620
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$210,784,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$172,823,180
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedmand · Leidos Biomedical Research, Inc.$105,458,370
Research focus
LaboratoriesWhole BloodSamplingValidationFollow-UpMonitorBlood SpecimenClinically RelevantUniversitiesResourcesWashingtonClinicViralReportingBaseRecombinaseComplexCostPaperProspectiveNucleic AcidsPolymeraseTransmission ProcessReaction
Grant awards (14)
Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics$752,475
R01 · FY2025 · AI · contact PI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$747,346
R01 · FY2025 · AI
Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics$776,510
R01 · FY2024 · AI · contact PI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$771,421
R01 · FY2024 · AI
Rapid, quantitative isothermal molecular assay for POC HIV-1 viral load monitoring using amplification nucleation site analysis$194,375
R21 · FY2024 · AI · contact PI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$771,422
R01 · FY2023 · AI
Rapid, quantitative isothermal molecular assay for POC HIV-1 viral load monitoring using amplification nucleation site analysis$233,250
R21 · FY2023 · AI · contact PI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$770,460
R01 · FY2022 · AI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$767,819
R01 · FY2021 · AI
Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acid amplification for viral pathogens in whole blood$484,674
R01 · FY2020 · EB · contact PI
Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acidamplification for viral pathogens in whole blood$413,677
R01 · FY2020 · EB · contact PI
Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acid amplification for viral pathogens in whole blood$413,677
R01 · FY2019 · EB · contact PI
Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acid amplification for viral pathogens in whole blood$437,529
R01 · FY2018 · EB · contact PI
Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acid amplification for viral pathogens in whole blood$488,906
R01 · FY2017 · EB · contact PI